Posted by Michael Wonder on 27 Oct 2021
Vertex's supplement to a new drug aubmission for Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 6-11 accepted for priority review by Health Canada
27 October 2021 - Vertex Pharmaceuticals today announced that its supplement to a new drug submission for Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) has been accepted for priority review by Health Canada for the treatment of cystic fibrosis in people ages 6-11 years.
Vertex will also submit this indication in parallel to both the Canadian Agency for Drugs and Technologies in Health and the Institut national d'excellence en santé et en services sociaux (INESSS) in Quebec for Health Technology Assessments.
